In HFpEF patients without atrial fibrillation or ischemic heart disease, β-blocker use was associated with a higher risk of mortality.
Does β-blocker use reduce mortality-related risk in HFpEF patients without AF or IHD?
Routine β-blocker use in HFpEF patients without atrial fibrillation or ischemic heart disease is associated with increased mortality risk and should be used with caution.
Absolute Event Rate: 0% vs 0%
In HFpEF patients without AF or IHD, β-blocker use was associated with higher mortality-related risk, indicating that routine β-blocker use in this subgroup should be interpreted with caution.
Nishino et al. (Wed,) reported a other. In HFpEF patients without atrial fibrillation or ischemic heart disease, β-blocker use was associated with a higher risk of mortality.